Efficacy Evaluation of Argatroban and Tirofiban in the Treatment of Transient Ischemic Attack
Objective:To evaluate the efficacy of argatroban and tirofiban in the treatment of transient ischemic attack(TIA).Methods:A retrospective analysis was performed on 196 patients with high-risk TIA admitted to the hospital from January 2020 to December 2021.They were divided into three groups:92 patients in group A,54 patients in group B and 50 patients in group C.Aspirin and clopidogrel bisulfate were given as dual antiplatelet therapy in Group A.Argatroban anticoagulation and Aspirin antiplatelet therapy were given in Group B.Tirofiban bridging aspirin and clopidogrel bisulfate were given as antiplatelet therapy in Group C.The therapeutic effects and adverse reactions of all patients were observed from the beginning of medication to 1 month.Results:The cure rate and total effective rate of group B and C were higher than those of group A,and the differences were statistically significant(χ2=4.955,20.787,5.600,10.762;P<0.05).The cure rate of group C was higher than that of group B,and the difference was statistically significant(χ2=4.630,P<0.05).The total effective rate of group C was slightly higher than that of group B,but the difference was not statistically significant(χ2=0.331,P>0.05).Conclusion:The efficacy of argatroban and tirofiban for TIA is significantly better than that of traditional dual antiplatelet therapy.In addition,studies have shown that argatroban and tirofiban have comparable overall response rates for TIA,but tirofiban may be able to prevent TIA recurrence and progression more quickly.
NETL
NSTL
万方数据
维普
